Description of Medical Areas
About the FDA Approved Listings
|
 |
Drugs Approved by the FDA (2004)
|
The following drugs have been approved this year by
the Food and Drug Administration.
Cardiology/Vascular Diseases
|
|
Dental/Maxillofacial Surgery
|
|
Dermatology/Plastic Surgery
|
|
Avastin (bevacizumab); For the treatment of metastatic carcinoma of the colon or rectum; Genentech; Approved February 2004 Erbitux (cetuximab); For the treatment of EGFR-expressing, metastatic colorectal cancer; Imclone, Bristol-Myers Squibb; Approved February 2004
Vidaza (azacitidine); For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias; Pharmion Corporation; Approved May 2004
Immunology/Infectious Diseases
|
|
Ketek (telithromycin); For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia.; Aventis Pharmaceuticals; Approved April 2004 Tindamax, tinidazole; For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis; Presutti Laboratories; Approved May, 2004 Xifaxan (rifaximin); For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli; Salix Pharmaceuticals; Approved May 2004
Vioxx (rofecoxib); For the treatment of rheumatoid arthritis; Merck; Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004
Fosrenol, lanthanum carbonate; For the treatment of hyperphosphatemia related to kidney dysfunction; Shire Pharmaceuticlas; Approved October, 2004 Sanctura (trospium chloride); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Indevus Pharmaceuticals; Approved May, 2004 Sensipar (cinacalcet); For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients; Amgen; Approved March 2004 Vesicare (solifenacin succinate); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Yamanouchi, GlaxoSmithKline; Approved November, 2004
Apokyn (apomorphine hydrochloride); For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinson’s disease; Mylan Bertek Pharmaceuticals; Approved April, 2004 Lunesta (eszopiclone); For the treatment of insomnia and sleep maintenance; Sepracor; Approved December 2004 Lyrica (pregabalin); For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; Pfizer; Approved December 2004 TYSABRI (natalizumab); For the treatment of relapsing forms of multiple sclerosis; Elan Pharmaceuticals / Biogen Idec; Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA
EstroGel (estradiol gel 0.06%); For the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause; Solvay Pharmaceuticals; Approved April 2004
Avastin (bevacizumab); For the treatment of metastatic carcinoma of the colon or rectum; Genentech; Approved February 2004 Clolar (clofarabine); For the treatment of acute lymphoblastic leukemia in pediatric patients; Genzyme; Approved December, 2004 Erbitux (cetuximab); For the treatment of EGFR-expressing, metastatic colorectal cancer; Imclone, Bristol-Myers Squibb; Approved February 2004 Sensipar (cinacalcet); For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients; Amgen; Approved March 2004 Tarceva (erlotinib, OSI 774); For the treatment of advanced refractory metastatic non-small cell lung cancer; Genentech, OSI Pharmaceuticals; Approved November, 2004
Macugen (pegaptanib); For the treatment of wet age-related macular degeneration.; Pfizer / Eyetech Pharmaceuticals; Approved December 2004
Campral (acamprosate calcium); For the treatment of alcohol dependence and the maintenance of alcohol abstinence; Forest Laboratories; Approved August, 2004
Pulmonary/Respiratory Diseases
|
|
Ketek (telithromycin); For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia.; Aventis Pharmaceuticals; Approved April 2004
Vioxx (rofecoxib); For the treatment of rheumatoid arthritis; Merck; Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004
Trauma/Emergency Medicine
|
|
|
|
Back to Centerwatch Drug Directories
|
